Assessment of a Novel RAR-γ Selective Agonist in vitro and in Combination Treatment With Immune Checkpoint Inhibition in vivo Using a Syngeneic Murine Lung Cancer Model

dc.contributorWei, Cheng-Hsin (Gina)
dc.contributorLiu, Xi (Hill)
dc.contributorDmitrovsky, Ethan
dc.contributor.advisorDmitrovsky, Ethan
dc.contributor.authorKreh, Blair
dc.contributor.departmentHood College Biology Departmenten_US
dc.contributor.programHood College Biomedical and Environmental Scienceen_US
dc.date.accessioned2022-04-18T14:33:06Z
dc.date.available2022-04-18T14:33:06Z
dc.date.issued2022-04-15
dc.description.abstractAll-trans retinoic acid (ATRA), an active metabolite of vitamin A (VA) and a pan-retinoic acid receptor (RAR) agonist, binds to RAR in the nucleus and signals induction or suppression of target genes. Colleagues previously observed that in vivo treatment of ATRA reduced BP (human melanoma) and ED1SQ4 (murine lung cancer) tumor growth in immunocompetent mice but not in immunodeficient mice, suggesting that the anti-tumor effects are mediated by the immune system. However, treatment of ATRA did not cooperate with immune checkpoint inhibition (anti-PD1) in vivo to further reduce tumor growth. In this study, we determined the effects of compound IRX4647, a novel RAR-γ selective agonist, treatment in vitro and in combination treatment with immune checkpoint inhibition (anti-PD-L1) in vivo. Our results showed that IRX4647 treatment in vitro altered growth and RAR/retinoid X receptor (RXR) expression differently in various lung cancer cell lines. Furthermore, IRX4647 cooperated with anti-PD-L1 in vivo by significantly reducing tumor volume in a 344SQ syngeneic murine model. We identified IL-5 and IL13 as immunophenotypic markers present in murine plasma and tumor tissue after treatment with the combination regimen. The precise mechanism related to the observation is still under investigation. This study provided insight in using a novel RAR-γ selective agonist in combination with immune checkpoint inhibition in vivo as an effective immunotherapy for lung cancer.en_US
dc.format.extent88 pagesen_US
dc.genreThesis (M.S.)en_US
dc.identifierdoi:10.13016/m2fv43-xs9e
dc.identifier.urihttp://hdl.handle.net/11603/24551
dc.language.isoen_USen_US
dc.relation.isAvailableAtHood College
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectRetinoic acid receptoren_US
dc.subjectall-trans retinoic aciden_US
dc.subjectImmunotherapyen_US
dc.subjectImmune checkpoint inhibitionen_US
dc.subjectLung canceren_US
dc.subjectPD-L1en_US
dc.titleAssessment of a Novel RAR-γ Selective Agonist in vitro and in Combination Treatment With Immune Checkpoint Inhibition in vivo Using a Syngeneic Murine Lung Cancer Modelen_US
dc.typeTexten_US
dcterms.creatorhttps://orcid.org/0000-0002-3858-2566en_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Master's Thesis - Blair Kreh.pdf
Size:
2.17 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.01 KB
Format:
Item-specific license agreed upon to submission
Description: